Converting checkpoint inhibitor (CPI)-resistant individuals to being responsive requires
identifying suppressive mechanisms. We identify TREM2+ tumor-associated macrophages …

Cancer immunotherapy can effectively inhibit cancer progression by activating the
autoimmune system, with low toxicity and high effectiveness. Some of cancer …

Immune-checkpoint blockade is able to achieve durable responses in a subset of patients;
however, we lack a satisfying comprehension of the underlying mechanisms of anti-CTLA-4 …

Simple Summary In the fight against cancer, immunotherapies have given great hope after
encouraging results in clinical investigations showing complete remission in some patients …

Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …

Cancer is a complex disease whose outcome depends largely on the cross-talk between the
tumor and its microenvironment. Here, we review the evolution of the field of tumor …

Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of …

FOXP3-expressing regulatory T (Treg) cells, which suppress aberrant immune response
against self-antigens, also suppress anti-tumor immune response. Infiltration of a large …

Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune
responses can regress tumors. However, this only occurs in a fraction of patients …

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …